NBIX250117C175000
- 0.00
- 0.000.00%
Neurocrine Biosciences Newsroom
Neurocrine Is Maintained at Overweight by Barclays
Piper Sandler Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $160
Wedbush Raises Price Target on Neurocrine Biosciences to $154 From $148, Keeps Outperform Rating
Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
Express News | Neurocrine Biosciences Inc : Jefferies Raises Target Price to $168 From $158
Teva Pharmaceutical, Li Auto, And Darden Restaurants Are Among Top Large Cap Gainers Last Week (December 16-20): Are The Others In Your Portfolio?
Needham Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating
TD Cowen Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $165
BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $182
TD Cowen Reaffirms Their Buy Rating on Neurocrine (NBIX)
Neurocrine Biosciences Starts Commercial Sales of New Congenital Adrenal Hyperplasia Treatment
Needham Reiterates Hold on Neurocrine Biosciencesto Hold
Express News | Neurocrine Biosciences Announces Commercial Availability of Crenessity™ (Crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Announces Target Price $185
A Quick Look at Today's Ratings for Neurocrine Biosciences(NBIX.US), With a Forecast Between $148 to $190
Express News | Neurocrine Biosciences Inc : JP Morgan Raises Target Price to $185 From $184
Summit Therapeutics Shares Are Trading Higher. The Stock May Be Moving in Sympathy With Neurocrine Biosciences Which Received FDA Approval for CRESNESSITY.
Neurocrine Biosciences Rises on FDA Nod for CAH Drug
Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential
Wedbush Reiterates Outperform on Neurocrine Biosciences, Maintains $148 Price Target